Clinical trials: Kidney Transplant Recipients
Kidney Transplant; Complications, Kidney Transplant Failure and Rejection
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
This investigator-initiated post-marketing study will evaluate the role of Hispanic ethnicity on drug dosing of Envarsus in first-time stable renal transplant recipients.
- Trial name
- NCT03438773
- Testing
- Envarsus, Tacrolimus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- California Institute of Renal Research
Unspecified Complications of Kidney Transplant, Disorder Related to Renal Transplantation
Evaluation of Sun Protection Education for Kidney Transplant Recipients
This study is being done to evaluate the effectiveness of a Sun Protection Strategies workbook for kidney transplant recipients.
- Trial name
- NCT01844713
- Testing
- Workbook
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- Northwestern University
Pancreas Transplantation, Kidney Transplantation
A Study To Compare Sirolimus Versus Tacrolimus In De Novo Simultaneous Pancreas- Kidney Allograft Recipients Receiving An Induction Therapy With Antithymocyte Globulin Plus Mycophenolate Mofetil Plus Corticosteroids
Experience with tacrolimus in pancreas transplantation has become a standard for immunosuppression in almost all pancreas centers over the world.
- Trial name
- NCT00693446
- Testing
- Sirolimus, Tacrolimus
- Where
- France
- Volunteers
- 118 people
- Sponsor
- Nantes University Hospital
Kidney Transplantation, BK Virus
IVIg to Treat BK Viremia in Kidney Transplant Recipients
The overall goal of this study is to rapidly improve clearance of BK viremia with Immunoglobulin (Privigen®) thereby decreasing the potential for formation of alloantibodies in renal transplant recipients that have had…
- Conditions
- Kidney Transplantation, BK Virus, Isoantibodies
- Trial name
- NCT02659891
- Testing
- IVIg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Massachusetts General Hospital
Renal Failure
Comparing Everolimus and Sirolimus in Renal Transplant Recipients
This study is being done to compare the effectiveness and safety of two different kidney transplant immunosuppression drugs, Zortress (the study drug) and Rapamune (which is used in the current standard immunosuppression regimen).
- Trial name
- NCT01976390
- Testing
- Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ohio State University
Kidney Transplant Rejection, Kidney Transplant; Complications
Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore
The investigators hypothesise that the adaptation of CYP3A5 genotype-based Tacrolimus (FK) dosing will lead to earlier FK target achievement and consequently, better clinical outcome after kidney transplantation (RTx).
- Trial name
- NCT04825262
- Testing
- Tacrolimus
- Where
- Singapore
- Volunteers
- 74 people
- Sponsor
- Singapore General Hospital
Kidney Transplant Recipient
Clinical Significance of 64-slice Multidetector Coronary CT Angiography to Evaluate the Prevalence and Severity of Coronary Artery Disease in Renal Transplant Recipients
The aim of this study is to evaluate the clinical usefulness of 64-slice multidetector coronary CT angiography (MDCTA) in renal transplant recipients who had no previous coronary artery disease (CAD).
- Trial name
- NCT01753505
- Testing
- 64-slice Multidetector coronary CT angiography
- Where
- South Korea
- Volunteers
- 93 people
- Sponsor
- Yonsei University
Renal Transplant Recipients
The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
This study evaluates the safety and availability of oral valganciclovir(VGC) at the does of 450mg daily begin within 10 days after renal transplantation, and till to Day 100 posttransplant.
- Trial name
- NCT02973464
- Testing
- Valganciclovir, Ganciclovir
- Where
- China
- Volunteers
- 450 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Kidney Transplantation, Ischemia-Reperfusion Injury
Thymoglobulin Induction in Kidney Transplant Recipients
The purpose of this study is to determine if anti-thymocyte globulin (Thymoglobuline) administration in the kidney transplant recipient is able to reduce the amount of damage that kidneys transplanted from deceased donors…
- Trial name
- TIKT (NCT01239563)
- Testing
- antithymocyte globulin, Basiliximab
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- University of Oxford
Antibody-mediated Rejection
A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR)
The purpose of this study is to assess the safety, tolerability, and efficacy of efgartigimod PH20 SC given by a prefilled syringe in participants with Antibody-Mediated Rejection (AMR) after kidney transplantation.
- Trial name
- Shamrock (NCT06503731)
- Testing
- Efgartigimod PH20 SC - prefilled syringe
- Where
- 23 sites in United States, Austria and 6 more
- Volunteers
- 33 people
- Sponsor
- argenx
Recipients of Liver Transplant
Envarsus XL Immunosuppression Following Liver Transplantation
The standard immunosuppressive regimen for liver transplantation includes twice daily tacrolimus (Prograf). In other transplantation models, there are potential benefits to extended release formulations as lower peak…
- Trial name
- NCT03828058
- Testing
- Envarsus XR, Prograf
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- Methodist Healthcare - Memphis
Urinary Tract Infections, Kidney Transplant Rejection
PRObiotics for KIdney Transplantation
The goal of this clinical trial is to assess if dietary supplememtation with OMNi-BiOTiC® 41167 reduces the risk of urinary tract infections in kidney transplant recipients.
- Conditions
- Urinary Tract Infections, Kidney Transplant Rejection, Kidney Transplant Infection, Dysbiosis
- Trial name
- ProKiT (NCT06825117)
- Testing
- OMNi-BiOTiC® 41167
- Where
- Italy
- Volunteers
- 132 people
- Sponsor
- University Hospital, Udine, Italy
Kidney Transplant Recipient, Diet Modification
Televideo Exercise and Nutrition Program for Kidney Transplant Recipients
The improvement in morbidity and mortality observed with kidney transplantation is often curtailed by post-transplant weight gain, which is common among kidney transplant recipients (KTR).
- Conditions
- Kidney Transplant Recipient, Diet Modification, Physical Activity
- Trial name
- NCT03697317
- Testing
- Televideo Lifestyle Coaching, Enhanced Usual Care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Kansas Medical Center
Kidney Failure
RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function
An unmet medical need exists for therapeutic regimens in transplantation that allow immediate postoperative graft function, thereby improving graft survival.
- Trial name
- NCT03791476
- Testing
- rhC1INH, Saline Solution
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Wisconsin, Madison
Kidney Transplantation
Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients
The study will evaluate kidney graft function in maintenance renal transplant patients.
- Trial name
- NCT00434590
- Testing
- Enteric coated mycophenolate sodium (Myfortic®)
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
Kidney Allograft Recipients in England - an Observational Cohort Study
Kidney transplantation is the renal replacement therapy of choice for the majority of patients with end-stage kidney disease. Epidemiological studies of kidney allograft recipients can aid in the understanding of cause and effect…
- Trial name
- KARE (NCT01798524)
- Where
- United Kingdom
- Volunteers
- 19,688 people
- Sponsor
- University Hospital Birmingham NHS Foundation Trust
Safety Issues, Chronic Hepatitis B
Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
tenofovir alafenamide (TAF) has been approved to be highly effective and safe in patients with chronic hepatitis B (CHB), therefore TAF may be a good option in kidney or liver transplant patients with chronic HBV infection.
- Conditions
- Safety Issues, Chronic Hepatitis B, Transplant Recipient
- Trial name
- NCT05410496
- Testing
- Tenofovir Alafenamide 25 MG
- Where
- 2 sites in Taiwan
- Volunteers
- 52 people
- Sponsor
- Taichung Veterans General Hospital
Herpes Zoster
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant
The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of 2 doses of PED-HZ/su, GSK's vaccine candidate for the prevention of Herpes Zoster (HZ) in immunocompromised paediatric renal transplant…
- Trial name
- NCT04006808
- Testing
- PED-HZ/su
- Where
- 31 sites in Belgium, France and 4 more
- Volunteers
- 184 people
- Sponsor
- GlaxoSmithKline
Delayed Graft Function
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
The purpose of this trial is to evaluate the reduction in incidence and severity of delayed graft function with kidney allografts from donors >45 years after brain death (DBD).
- Trial name
- ReGIFT (NCT02610296)
- Testing
- QPI-1002
- Where
- 84 sites in United States, Argentina and 9 more
- Volunteers
- 594 people
- Sponsor
- Quark Pharmaceuticals
COVID-19, Kidney Transplant
COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
An open label, non-randomized pilot study in kidney transplant recipients who received a completed primary series and bivalent booster of mRNA based COVID-19 vaccine and have ≤2500 U/mL SARS-CoV-2 S antibody concentration using…
- Trial name
- CPAT-SG (NCT05518487)
- Testing
- Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.